Market Research Logo

Antibacterial Therapies Drug Development Pipeline Review, 2017

Antibacterial Therapies Drug Development Pipeline Review, 2017

Summary


The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.

There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the market, and accounts for approximately 25% of the pipeline.

Currently, drugs for the prevention of bacterial infections are typically vaccines which help to train the body’s immune system to fight off bacterial infections caused by specific bacterial strains. However, several prophylactic monoclonal antibodies are now in the pipeline and may impact the market in the near future.

Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, such as penicillin, and protein synthesis inhibitors. However, bacterial resistance has reduced the efficacy of many of these drugs. As a result the pipeline includes a variety of new-generation protein synthesis inhibitors and beta-lactam/beta-lactamase inhibitor combination drugs, which are active against currently hard to treat bacterial strains.

The report provides comprehensive information on the pipeline development landscape for Pneumonia, Methicillin-resistant staphylococcus aureus (MRSA) and Tuberculosis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

  • Which companies are the most active within the pipeline for antibacterial drugs?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • Executive Summary
  • Introduction
    • GBI Research Report Coverage
    • Tuberculosis Overview
    • Pneumonia
      • Community Acquired Pneumonia Overview
      • Hospital Acquired Pneumonia (HAP) Overview
      • Ventilator Associated Pneumonia (VAP) Overview
      • Pseudomonas aeruginosa Infections Overview
      • Klebsiella pneumoniae Infections Overview
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Overview
      • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections Overview
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Overview
  • Therapeutics Development
    • Tuberculosis
      • Pipeline Products for Tuberculosis - Overview
        • Table Figure 1: Number of Products under Development for Tuberculosis
        • Table Number of Products under Development for Tuberculosis
      • Pipeline Products for Tuberculosis - Comparative Analysis
        • Table Figure 2: Number of Products under Development for Tuberculosis - Comparative Analysis
        • Table Number of Products under Development for Tuberculosis - Comparative Analysis
    • Pneumonia
      • Community Acquired Pneumonia
        • Table Figure 3: Number of Products under Development for Community Acquired Pneumonia
        • Table Number of Products under Development for Community Acquired Pneumonia
        • Table Number of Products under Development for Hospital Community Acquired Pneumonia (HAP) - Comparative Analysis
      • Hospital Acquired Pneumonia (HAP)
        • Table Figure 4: Number of Products under Development for Hospital Acquired Pneumonia (HAP)
        • Table Number of Products under Development for Hospital Acquired Pneumonia (HAP)
      • Pipeline Products for Hospital Acquired Pneumonia (HAP) - Comparative Analysis
        • Table Figure 5: Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis
        • Table Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis
      • Ventilator Associated Pneumonia (VAP)
        • Table Figure 6: Number of Products under Development for Ventilator Associated Pneumonia (VAP)
        • Table Number of Products under Development for Ventilator Associated Pneumonia (VAP)
      • Pipeline Products for Ventilator Associated Pneumonia (VAP) - Comparative Analysis
        • Table Figure 7: Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis
        • Table Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis
      • Pseudomonas aeruginosa Infections
        • Table Figure 8: Number of Products under Development for Pseudomonas aeruginosa Infections
        • Table Number of Products under Development for Pseudomonas aeruginosa Infections
      • Pipeline Products for Pseudomonas aeruginosa Infections - Comparative Analysis
        • Table Figure 9: Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis
        • Table Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis
      • Klebsiella pneumoniae Infections
        • Table Figure 10: Number of Products under Development for Klebsiella pneumoniae Infections
        • Table Number of Products under Development for Klebsiella pneumoniae Infections
      • Pipeline Products for Klebsiella pneumoniae Infections - Comparative Analysis
        • Table Figure 11: Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis
        • Table Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Figure 12: Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Pipeline Products for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis
        • Table Figure 13: Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis
        • Table Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis
      • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Figure 14: Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Figure 15: Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
      • Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis
        • Table Figure 16: Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis
        • Table Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis
  • Therapeutics under Development by Companies
    • Tuberculosis
      • Table Figure 17: Number of Products under Development by Companies, Tuberculosis
      • Table Number of Products under Development by Companies, Tuberculosis
    • Pneumonia
      • Community Acquired Pneumonia
        • Table Figure 18: Number of Products under Development by Companies, Community Acquired Pneumonia
        • Table Number of Products under Development by Companies, Community Acquired Pneumonia
      • Hospital Acquired Pneumonia (HAP)
        • Table Figure 19: Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP)
        • Table Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP)
      • Ventilator Associated Pneumonia (VAP)
        • Table Figure 20: Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP)
        • Table Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP)
      • Pseudomonas aeruginosa Infections
        • Table Figure 21: Number of Products under Development by Companies, Pseudomonas aeruginosa Infections
        • Table Number of Products under Development by Companies, Pseudomonas aeruginosa Infections
      • Klebsiella pneumoniae Infections
        • Table Figure 22: Number of Products under Development by Companies, Klebsiella pneumoniae Infections
        • Table Number of Products under Development by Companies, Klebsiella pneumoniae Infections
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Figure 23: Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Figure 24: Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Figure 25: Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Therapeutics under Investigation by Universities/Institutes
    • Tuberculosis
      • Table Figure 26: Number of Products under Investigation by Universities/Institutes, Tuberculosis
      • Table Number of Products under Investigation by Universities/Institutes, Tuberculosis
    • Pneumonia
      • Hospital Acquired Pneumonia (HAP)
        • Table Number of Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP)
      • Ventilator Associated Pneumonia (VAP)
        • Table Number of Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP)
      • Pseudomonas aeruginosa Infections
        • Table Figure 27: Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections
        • Table Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections
      • Klebsiella pneumoniae Infections
        • Table Figure 28: Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections
        • Table Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Figure 29: Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Number of Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Pipeline Products Glance
    • Tuberculosis
      • Late Stage Products
        • Table Figure 30: Comparative Analysis by Late Stage Development, Tuberculosis
        • Table Comparative Analysis by Late Stage Development, Tuberculosis
      • Clinical Stage Products
        • Table Figure 31: Comparative Analysis by Clinical Stage Development, Tuberculosis
        • Table Comparative Analysis by Clinical Stage Development, Tuberculosis
      • Early Stage Products
        • Table Figure 32: Comparative Analysis by Early Stage Products, Tuberculosis
        • Table Comparative Analysis by Early Stage Development, Tuberculosis
      • Unknown Stage Products
        • Table Comparative Analysis by Unknown Stage Development, Tuberculosis
    • Pneumonia
      • Community Acquired Pneumonia
        • Table Figure 33: Comparative Analysis by Late Stage Development, Community Acquired Pneumonia
        • Table Comparative Analysis by Late Stage Development, Community Acquired Pneumonia
      • Clinical Stage Products
        • Table Figure 34: Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia
        • Table Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia
      • Early Stage Products
        • Table Figure 35: Comparative Analysis by Early Stage Products, Community Acquired Pneumonia
        • Table Comparative Analysis by Early Stage Development, Community Acquired Pneumonia
      • Hospital Acquired Pneumonia (HAP)
        • Table Comparative Analysis by Late Stage Development, Hospital Acquired Pneumonia (HAP)
      • Clinical Stage Products
        • Table Figure 36: Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP)
        • Table Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP)
      • Early Stage Products
        • Table Figure 37: Comparative Analysis by Early Stage Products, Hospital Acquired Pneumonia (HAP)
        • Table Comparative Analysis by Early Stage Development, Hospital Acquired Pneumonia (HAP)
      • Unknown Stage Products
        • Table Comparative Analysis by Unknown Stage Development, Hospital Acquired Pneumonia (HAP)
      • Ventilator Associated Pneumonia (VAP)
        • Table Figure 38: Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP)
        • Table Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP)
      • Clinical Stage Products
        • Table Figure 39: Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP)
        • Table Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP)
      • Early Stage Products
        • Table Figure 40: Comparative Analysis by Early Stage Products, Ventilator Associated Pneumonia (VAP)
        • Table Comparative Analysis by Early Stage Development, Ventilator Associated Pneumonia (VAP)
      • Unknown Stage Products
        • Table Figure 41: Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP)
        • Table Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP)
      • Pseudomonas aeruginosa Infections
        • Table Figure 42: Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections
        • Table Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections
      • Clinical Stage Products
        • Table Figure 43: Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections
        • Table Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections
      • Early Stage Products
        • Table Figure 44: Comparative Analysis by Early Stage Products, Pseudomonas aeruginosa Infections
        • Table Comparative Analysis by Early Stage Development, Pseudomonas aeruginosa Infections
      • Unknown Stage Products
        • Table Figure 45: Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections
        • Table Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections
      • Klebsiella pneumoniae Infections
        • Table Comparative Analysis by Late Stage Development, Klebsiella pneumoniae Infections
      • Clinical Stage Products
        • Table Comparative Analysis by Clinical Stage Development, Klebsiella pneumoniae Infections
      • Early Stage Products
        • Table Figure 46: Comparative Analysis by Early Stage Products, Klebsiella pneumoniae Infections
        • Table Comparative Analysis by Early Stage Development, Klebsiella pneumoniae Infections
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Comparative Analysis by Late Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Clinical Stage Products
        • Table Figure 47: Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA)
        • Table Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Early Stage Products
        • Table Figure 48: Comparative Analysis by Early Stage Products, Methicillin-Resistant Staphylococcus aureus (MRSA)
        • Table Comparative Analysis by Early Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Unknown Stage Products
        • Table Comparative Analysis by Unknown Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Comparative Analysis by Clinical Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
      • Early Stage Products
        • Table Comparative Analysis by Early Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Comparative Analysis by Clinical Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
      • Early Stage Products
        • Table Figure 49: Comparative Analysis by Early Stage Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Comparative Analysis by Early Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Products under Development by Companies
    • Tuberculosis
      • Table Products under Development by Companies, Tuberculosis
    • Pneumonia
      • Community Acquired Pneumonia
        • Table Products under Development by Companies, Community Acquired Pneumonia
      • Hospital Acquired Pneumonia (HAP)
        • Table Products under Development by Companies, Hospital Acquired Pneumonia (HAP)
      • Ventilator Associated Pneumonia (VAP)
        • Table Products under Development by Companies, Ventilator Associated Pneumonia (VAP)
      • Pseudomonas aeruginosa Infections
        • Table Products under Development by Companies, Pseudomonas aeruginosa Infections
      • Klebsiella pneumoniae Infections
        • Table Products under Development by Companies, Klebsiella pneumoniae Infections
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Products under Investigation by Universities/Institutes
    • Tuberculosis
      • Table Products under Investigation by Universities/Institutes, Tuberculosis
    • Pneumonia
      • Hospital Acquired Pneumonia (HAP)
        • Table Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP)
      • Ventilator Associated Pneumonia (VAP)
        • Table Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP)
      • Pseudomonas aeruginosa Infections
        • Table Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections
      • Klebsiella pneumoniae Infections
        • Table Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Companies Involved in Therapeutics Development
    • Tuberculosis
      • Abera Bioscience AB
        • Table Tuberculosis - Pipeline by Abera Bioscience AB,
      • Akthelia Pharmaceuticals Limited
        • Table Tuberculosis - Pipeline by Akthelia Pharmaceuticals Limited,
      • Alvogen Korea Co., Ltd.
        • Table Tuberculosis - Pipeline by Alvogen Korea Co., Ltd.,
      • Anacor Pharmaceuticals, Inc.
        • Table Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc.,
      • Archivel Farma S.L.
        • Table Tuberculosis - Pipeline by Archivel Farma S.L.,
      • AstraZeneca Plc
        • Table Tuberculosis - Pipeline by AstraZeneca Plc,
      • Beech Tree Labs, Inc.
        • Table Tuberculosis - Pipeline by Beech Tree Labs, Inc.,
      • BioDiem Ltd
        • Table Tuberculosis - Pipeline by BioDiem Ltd,
      • BioLingus AG
        • Table Tuberculosis - Pipeline by BioLingus AG,
      • Biomar Microbial Technologies
        • Table Tuberculosis - Pipeline by Biomar Microbial Technologies,
      • Bioversys AG
        • Table Tuberculosis - Pipeline by Bioversys AG,
      • Celgene Corporation
        • Table Tuberculosis - Pipeline by Celgene Corporation,
      • Cellceutix Corporation
        • Table Tuberculosis - Pipeline by Cellceutix Corporation,
      • Chongqing Zhifei Biological Products Co., Ltd.
        • Table Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd.,
      • Crestone, Inc.
        • Table Tuberculosis - Pipeline by Crestone, Inc.,
      • Dafra Pharma International Ltd.
        • Table Tuberculosis - Pipeline by Dafra Pharma International Ltd.,
      • Daiichi Sankyo Company, Limited
        • Table Tuberculosis - Pipeline by Daiichi Sankyo Company, Limited,
      • Demuris Limited
        • Table Tuberculosis - Pipeline by Demuris Limited,
      • Eisai Co., Ltd.
        • Table Tuberculosis - Pipeline by Eisai Co., Ltd.,
      • Eli Lilly and Company
        • Table Tuberculosis - Pipeline by Eli Lilly and Company,
      • Ensol Biosciences Inc.
        • Table Tuberculosis - Pipeline by Ensol Biosciences Inc.,
      • EpiVax, Inc.
        • Table Tuberculosis - Pipeline by EpiVax, Inc.,
      • FIT Biotech Oy
        • Table Tuberculosis - Pipeline by FIT Biotech Oy,
      • GangaGen Inc.
        • Table Tuberculosis - Pipeline by GangaGen Inc.,
      • GlaxoSmithKline Plc
        • Table Tuberculosis - Pipeline by GlaxoSmithKline Plc,
      • Globeimmune, Inc.
        • Table Tuberculosis - Pipeline by Globeimmune, Inc.,
      • Hager Biosciences, LLC
        • Table Tuberculosis - Pipeline by Hager Biosciences, LLC,
      • Hsiri Therapeutics LLC
        • Table Tuberculosis - Pipeline by Hsiri Therapeutics LLC,
      • Imaxio SA
        • Table Tuberculosis - Pipeline by Imaxio SA,
      • Immunitor, Inc.
        • Table Tuberculosis - Pipeline by Immunitor, Inc.,
      • ImmunoBiology Limited
        • Table Tuberculosis - Pipeline by ImmunoBiology Limited,
      • Inovio Pharmaceuticals, Inc.
        • Table Tuberculosis - Pipeline by Inovio Pharmaceuticals, Inc.,
      • Johnson & Johnson
        • Table Tuberculosis - Pipeline by Johnson & Johnson,
      • Lakewood-Amedex Inc
        • Table Tuberculosis - Pipeline by Lakewood-Amedex Inc,
      • Lipotek Pty Ltd.
        • Table Tuberculosis - Pipeline by Lipotek Pty Ltd.,
      • Matinas BioPharma Holdings, Inc.
        • Table Tuberculosis - Pipeline by Matinas BioPharma Holdings, Inc. ,
      • Microbion Corporation
        • Table Tuberculosis - Pipeline by Microbion Corporation,
      • Microbiotix, Inc.
        • Table Tuberculosis - Pipeline by Microbiotix, Inc.,
      • NEARMEDIC PLUS, Ltd
        • Table Tuberculosis - Pipeline by NEARMEDIC PLUS, Ltd,
      • Novartis AG
        • Table Tuberculosis - Pipeline by Novartis AG,
      • NovoBiotic Pharmaceuticals, LLC
        • Table Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals, LLC,
      • Otsuka Holdings Co., Ltd.
        • Table Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd.,
      • QureTech Bio AB
        • Table Tuberculosis - Pipeline by QureTech Bio AB,
      • Recce Pty Ltd
        • Table Tuberculosis - Pipeline by Recce Pty Ltd,
      • Rodos BioTarget GmbH
        • Table Tuberculosis - Pipeline by Rodos BioTarget GmbH,
      • Sanofi
        • Table Tuberculosis - Pipeline by Sanofi,
      • Sanofi Pasteur SA
        • Table Tuberculosis - Pipeline by Sanofi Pasteur SA,
      • Sarepta Therapeutics, Inc.
        • Table Tuberculosis - Pipeline by Sarepta Therapeutics, Inc.,
      • Sequella, Inc.
        • Table Tuberculosis - Pipeline by Sequella, Inc.,
      • Shionogi & Co., Ltd.
        • Table Tuberculosis - Pipeline by Shionogi & Co., Ltd.,
      • Sphaera Pharma Pvt. Ltd.
        • Table Tuberculosis - Pipeline by Sphaera Pharma Pvt. Ltd.,
      • Spring Bank Pharmaceuticals, Inc.
        • Table Tuberculosis - Pipeline by Spring Bank Pharmaceuticals, Inc.,
      • Takeda Pharmaceutical Company Limited
        • Table Tuberculosis - Pipeline by Takeda Pharmaceutical Company Limited,
      • TetraLogic Pharmaceuticals
        • Table Tuberculosis - Pipeline by TetraLogic Pharmaceuticals,
      • TGV-Laboratories
        • Table Tuberculosis - Pipeline by TGV-Laboratories,
      • Theravectys SA
        • Table Tuberculosis - Pipeline by Theravectys SA,
      • Tomegavax, Inc.
        • Table Tuberculosis - Pipeline by Tomegavax, Inc.,
      • Transgene SA
        • Table Tuberculosis - Pipeline by Transgene SA,
      • TVAX Biomedical, Inc.
        • Table Tuberculosis - Pipeline by TVAX Biomedical, Inc.,
      • Univalue Valorizacion, S.L.
        • Table Tuberculosis - Pipeline by Univalue Valorizacion, S.L.,
      • Vaccibody AS
        • Table Tuberculosis - Pipeline by Vaccibody AS,
      • Vakzine Projekt Management GmbH
        • Table Tuberculosis - Pipeline by Vakzine Projekt Management GmbH,
      • Vaxil Bio Therapeutics Ltd.
        • Table Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd.,
      • Vichem Chemie Research Ltd.
        • Table Tuberculosis - Pipeline by Vichem Chemie Research Ltd.,
    • Pneumonia
      • Community Acquired Pneumonia
        • Table Community Acquired Pneumonia - Pipeline by Aridis Pharmaceuticals LLC,
      • BioAegis Therapeutics, Inc.
        • Table Community Acquired Pneumonia - Pipeline by BioAegis Therapeutics, Inc.,
      • Biotest AG
        • Table Community Acquired Pneumonia - Pipeline by Biotest AG,
      • C10 Pharma AS
        • Table Community Acquired Pneumonia - Pipeline by C10 Pharma AS,
      • InflaRx GmbH
        • Table Community Acquired Pneumonia - Pipeline by InflaRx GmbH,
      • ioGenetics, Inc.
        • Table Community Acquired Pneumonia - Pipeline by ioGenetics, Inc.,
      • Kyorin Pharmaceutical Co., Ltd.
        • Table Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd.,
      • Lascco SA
        • Table Community Acquired Pneumonia - Pipeline by Lascco SA,
      • Melinta Therapeutics, Inc
        • Table Community Acquired Pneumonia - Pipeline by Melinta Therapeutics, Inc,
      • Merck & Co., Inc.
        • Table Community Acquired Pneumonia - Pipeline by Merck & Co., Inc.,
      • Nabriva Therapeutics AG
        • Table Community Acquired Pneumonia - Pipeline by Nabriva Therapeutics AG,
      • Paratek Pharmaceuticals, Inc.
        • Table Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc.,
      • TaiGen Biotechnology Co., Ltd.
        • Table Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co., Ltd.,
      • Takeda Pharmaceutical Company Limited
        • Table Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Limited,
      • Tetraphase Pharmaceuticals Inc.
        • Table Community Acquired Pneumonia - Pipeline by Tetraphase Pharmaceuticals Inc.,
      • TiGenix NV
        • Table Community Acquired Pneumonia - Pipeline by TiGenix NV,
      • Hospital Acquired Pneumonia (HAP)
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc.,
      • Adenium Biotech ApS
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS,
      • Aridis Pharmaceuticals LLC
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC,
      • AstraZeneca Plc
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc,
      • Bayer AG
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG,
      • Cardeas Pharma Corp.
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp.,
      • MedImmune, LLC
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune, LLC,
      • Meiji Seika Pharma Co., Ltd.
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co., Ltd.,
      • Melinta Therapeutics, Inc
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics, Inc,
      • Merck & Co., Inc.
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co., Inc.,
      • Motif Bio Plc
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc,
      • Nabriva Therapeutics AG
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG,
      • Savara Inc.
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Savara Inc.,
      • Sealife PHARMA GMBH
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH,
      • Shionogi & Co., Ltd.
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co., Ltd.,
      • Tetraphase Pharmaceuticals Inc.
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc.,
      • Wockhardt Limited
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Limited,
      • Zavante Therapeutics, Inc.
        • Table Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics, Inc.,
      • Ventilator Associated Pneumonia (VAP)
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Achaogen Inc.,
      • Adenium Biotech ApS
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS,
      • Aridis Pharmaceuticals LLC
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC,
      • AstraZeneca Plc
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc,
      • Bayer AG
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Bayer AG,
      • Cardeas Pharma Corp.
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp.,
      • MedImmune, LLC
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune, LLC,
      • Meiji Seika Pharma Co., Ltd.
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co., Ltd.,
      • Merck & Co., Inc.
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co., Inc.,
      • Motif Bio Plc
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc,
      • Nabriva Therapeutics AG
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics AG,
      • Savara Inc.
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Savara Inc.,
      • Shionogi & Co., Ltd.
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co., Ltd.,
      • Tetraphase Pharmaceuticals Inc.
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc.,
      • Zavante Therapeutics, Inc.
        • Table Ventilator Associated Pneumonia (VAP) - Pipeline by Zavante Therapeutics, Inc.,
      • Pseudomonas aeruginosa Infections
        • Table Pseudomonas aeruginosa Infections - Pipeline by Achaogen Inc,
      • Adenium Biotech ApS
        • Table Pseudomonas aeruginosa Infections - Pipeline by Adenium Biotech ApS,
      • Aeolus Pharmaceuticals Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Aeolus Pharmaceuticals Inc,
      • AlgiPharma AS
        • Table Pseudomonas aeruginosa Infections - Pipeline by AlgiPharma AS,
      • AmpliPhi Biosciences Corp
        • Table Pseudomonas aeruginosa Infections - Pipeline by AmpliPhi Biosciences Corp,
      • AnGes MG Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by AnGes MG Inc,
      • Arch Biopartners, Inc.
        • Table Pseudomonas aeruginosa Infections - Pipeline by Arch Biopartners, Inc.,
      • Aridis Pharmaceuticals LLC
        • Table Pseudomonas aeruginosa Infections - Pipeline by Aridis Pharmaceuticals LLC,
      • Arno Therapeutics Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Arno Therapeutics Inc,
      • AstraZeneca Plc
        • Table Pseudomonas aeruginosa Infections - Pipeline by AstraZeneca Plc,
      • Biolytics Pharma
        • Table Pseudomonas aeruginosa Infections - Pipeline by Biolytics Pharma,
      • Catabasis Pharmaceuticals Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Catabasis Pharmaceuticals Inc,
      • Cellceutix Corp
        • Table Pseudomonas aeruginosa Infections - Pipeline by Cellceutix Corp,
      • CSA Biotechnologies LLC
        • Table Pseudomonas aeruginosa Infections - Pipeline by CSA Biotechnologies LLC,
      • Cyclacel Pharmaceuticals Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Cyclacel Pharmaceuticals Inc,
      • Evaxion Biotech ApS
        • Table Pseudomonas aeruginosa Infections - Pipeline by Evaxion Biotech ApS,
      • F. Hoffmann-La Roche Ltd
        • Table Pseudomonas aeruginosa Infections - Pipeline by F. Hoffmann-La Roche Ltd,
      • FOB Synthesis Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by FOB Synthesis Inc,
      • GlaxoSmithKline Plc
        • Table Pseudomonas aeruginosa Infections - Pipeline by GlaxoSmithKline Plc,
      • Helix BioMedix Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Helix BioMedix Inc,
      • Hsiri Therapeutics LLC
        • Table Pseudomonas aeruginosa Infections - Pipeline by Hsiri Therapeutics LLC,
      • Immun System IMS AB
        • Table Pseudomonas aeruginosa Infections - Pipeline by Immun System IMS AB,
      • Insmed Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Insmed Inc,
      • Lascco SA
        • Table Pseudomonas aeruginosa Infections - Pipeline by Lascco SA,
      • Laurent Pharmaceuticals Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Laurent Pharmaceuticals Inc,
      • LegoChem Biosciences Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by LegoChem Biosciences Inc,
      • Lytix Biopharma AS
        • Table Pseudomonas aeruginosa Infections - Pipeline by Lytix Biopharma AS,
      • MedImmune LLC
        • Table Pseudomonas aeruginosa Infections - Pipeline by MedImmune LLC,
      • Melinta Therapeutics Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Melinta Therapeutics Inc,
      • Microbiotix Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Microbiotix Inc,
      • Nosopharm SAS
        • Table Pseudomonas aeruginosa Infections - Pipeline by Nosopharm SAS,
      • Novabiotics Ltd
        • Table Pseudomonas aeruginosa Infections - Pipeline by Novabiotics Ltd,
      • Omnia Molecular Ltd
        • Table Pseudomonas aeruginosa Infections - Pipeline by Omnia Molecular Ltd,
      • Peptilogics Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Peptilogics Inc,
      • Pfizer Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Pfizer Inc,
      • Pherecydes Pharma SA
        • Table Pseudomonas aeruginosa Infections - Pipeline by Pherecydes Pharma SA,
      • Phico Therapeutics Ltd
        • Table Pseudomonas aeruginosa Infections - Pipeline by Phico Therapeutics Ltd,
      • Polyphor Ltd
        • Table Pseudomonas aeruginosa Infections - Pipeline by Polyphor Ltd,
      • Procarta Biosystems Ltd
        • Table Pseudomonas aeruginosa Infections - Pipeline by Procarta Biosystems Ltd,
      • Sanofi
        • Table Pseudomonas aeruginosa Infections - Pipeline by Sanofi,
      • Sarepta Therapeutics Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Sarepta Therapeutics Inc,
      • Sealife PHARMA GMBH
        • Table Pseudomonas aeruginosa Infections - Pipeline by Sealife PHARMA GMBH,
      • Sequoia Sciences Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Sequoia Sciences Inc,
      • Shionogi & Co Ltd
        • Table Pseudomonas aeruginosa Infections - Pipeline by Shionogi & Co Ltd,
      • Soligenix Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Soligenix Inc,
      • Syntiron LLC
        • Table Pseudomonas aeruginosa Infections - Pipeline by Syntiron LLC,
      • Tetraphase Pharmaceuticals Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Tetraphase Pharmaceuticals Inc,
      • Varinel Inc
        • Table Pseudomonas aeruginosa Infections - Pipeline by Varinel Inc,
      • Vaxdyn SL
        • Table Pseudomonas aeruginosa Infections - Pipeline by Vaxdyn SL,
      • Zambon Company SpA
        • Table Pseudomonas aeruginosa Infections - Pipeline by Zambon Company SpA,
      • Klebsiella pneumoniae Infections
        • Table Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc,
      • Arsanis, Inc.
        • Table Klebsiella pneumoniae Infections - Pipeline by Arsanis, Inc.,
      • Cellceutix Corporation
        • Table Klebsiella pneumoniae Infections - Pipeline by Cellceutix Corporation,
      • Debiopharm International SA
        • Table Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA ,
      • Evaxion Biotech ApS
        • Table Klebsiella pneumoniae Infections - Pipeline by Evaxion Biotech ApS,
      • F. Hoffmann-La Roche Ltd.
        • Table Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd.,
      • FOB Synthesis, Inc.
        • Table Klebsiella pneumoniae Infections - Pipeline by FOB Synthesis, Inc.,
      • Melinta Therapeutics, Inc
        • Table Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics, Inc,
      • Merck & Co., Inc.
        • Table Klebsiella pneumoniae Infections - Pipeline by Merck & Co., Inc.,
      • MicuRx Pharmaceuticals, Inc.
        • Table Klebsiella pneumoniae Infections - Pipeline by MicuRx Pharmaceuticals, Inc.,
      • Nosopharm SAS
        • Table Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS,
      • Peptilogics, Inc.
        • Table Klebsiella pneumoniae Infections - Pipeline by Peptilogics, Inc.,
      • Pfizer Inc.
        • Table Klebsiella pneumoniae Infections - Pipeline by Pfizer Inc.,
      • Phico Therapeutics Limited
        • Table Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Limited,
      • Procarta Biosystems Limited
        • Table Klebsiella pneumoniae Infections - Pipeline by Procarta Biosystems Limited,
      • Sarepta Therapeutics, Inc.
        • Table Klebsiella pneumoniae Infections - Pipeline by Sarepta Therapeutics, Inc.,
      • Shionogi & Co., Ltd.
        • Table Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co., Ltd.,
      • Soligenix, Inc.
        • Table Klebsiella pneumoniae Infections - Pipeline by Soligenix, Inc.,
      • Sumitomo Dainippon Pharma Co., Ltd.
        • Table Klebsiella pneumoniae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd.,
      • Syntiron LLC
        • Table Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC,
      • Tetraphase Pharmaceuticals Inc.
        • Table Klebsiella pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc.,
      • Varinel, Inc.
        • Table Klebsiella pneumoniae Infections - Pipeline by Varinel, Inc.,
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth Biologics Limited,
      • Actelion Ltd
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Actelion Ltd,
      • Adenium Biotech ApS
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Adenium Biotech ApS,
      • AIMM Therapeutics B.V.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AIMM Therapeutics B.V.,
      • Alchemia Limited
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alchemia Limited,
      • Allergan Plc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Allergan Plc,
      • AlphaMab Co., Ltd
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AlphaMab Co., Ltd,
      • Alvogen Korea Co., Ltd.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Alvogen Korea Co., Ltd.,
      • AmpliPhi Biosciences Corporation
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AmpliPhi Biosciences
      • AnGes MG, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AnGes MG, Inc.,
      • Antibiotx ApS
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Antibiotx ApS,
      • Aphios Corporation
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aphios Corporation,
      • Aridis Pharmaceuticals LLC
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Aridis Pharmaceuticals LLC,
      • Arsanis, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Arsanis, Inc.,
      • AstraZeneca Plc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AstraZeneca Plc,
      • Atriva Therapeutics GmbH
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Atriva Therapeutics GmbH,
      • Bavarian Nordic A/S
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bavarian Nordic A/S,
      • Bharat Biotech International Limited
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Bharat Biotech International
      • C3 Jian, Inc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by C3 Jian, Inc,
      • Cellceutix Corporation
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cellceutix Corporation,
      • Cempra Inc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Cempra Inc,
      • Citius Pharmaceuticals, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Citius Pharmaceuticals, Inc.,
      • Common Pharma Inc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Common Pharma Inc,
      • ContraFect Corporation
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ContraFect Corporation,
      • Crestone, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Crestone, Inc.,
      • Critical Outcome Technologies Inc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Critical Outcome
      • CrystalGenomics, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CrystalGenomics, Inc.,
      • CSA Biotechnologies LLC
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by CSA Biotechnologies LLC ,
      • Debiopharm International SA
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Debiopharm International SA ,
      • Dermala Inc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Dermala Inc,
      • DesignMedix, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by DesignMedix, Inc.,
      • Destiny Pharma Limited
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Destiny Pharma Limited,
      • Dong-A Socio Holdings Co. Ltd.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Dong-A Socio Holdings Co.
      • e-Therapeutics Plc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by e-Therapeutics Plc,
      • Emergent BioSolutions Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Emergent BioSolutions Inc.,
      • Ensol Biosciences Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ensol Biosciences Inc.,
      • Excelimmune, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Excelimmune, Inc.,
      • Galapagos NV
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Galapagos NV,
      • GangaGen Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by GangaGen Inc.,
      • Gero Corp
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Gero Corp,
      • Helix BioMedix, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Helix BioMedix, Inc.,
      • Hsiri Therapeutics LLC
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Hsiri Therapeutics LLC,
      • Ildong Pharmaceutical Co., Ltd.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Ildong Pharmaceutical Co.,
      • Immupharma Plc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Immupharma Plc,
      • iNtRON Biotechnology Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by iNtRON Biotechnology Inc.,
      • ioGenetics, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by ioGenetics, Inc.,
      • Kyorin Pharmaceutical Co., Ltd.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Kyorin Pharmaceutical Co.,
      • Lascco SA
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lascco SA,
      • LegoChem Biosciences, Inc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by LegoChem Biosciences, Inc,
      • Lipocure Ltd.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Lipocure Ltd.,
      • Madam Therapeutics B.V.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Madam Therapeutics B.V.,
      • Melinta Therapeutics, Inc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Melinta Therapeutics, Inc,
      • Merck & Co., Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Merck & Co., Inc.,
      • Microbiotix, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Microbiotix, Inc.,
      • MicuRx Pharmaceuticals, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MicuRx Pharmaceuticals, Inc.,
      • MorphoSys AG
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by MorphoSys AG,
      • Motif Bio Plc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Motif Bio Plc,
      • Nabriva Therapeutics AG
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nabriva Therapeutics AG,
      • Nemus Bioscience, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Nemus Bioscience, Inc.,
      • Novabiotics Limited
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Novabiotics Limited,
      • NovaDigm Therapeutics, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovaDigm Therapeutics, Inc.,
      • NovoBiotic Pharmaceuticals, LLC
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by NovoBiotic Pharmaceuticals,
      • Omnia Molecular Ltd.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Omnia Molecular Ltd.,
      • Oragenics, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Oragenics, Inc.,
      • Pfizer Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Pfizer Inc.,
      • Phico Therapeutics Limited
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Phico Therapeutics Limited,
      • Procarta Biosystems Limited
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Procarta Biosystems Limited,
      • Prommune, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Prommune, Inc.,
      • Recce Pty Ltd
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Recce Pty Ltd,
      • Redx Pharma Plc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Redx Pharma Plc,
      • Sarepta Therapeutics, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sarepta Therapeutics, Inc.,
      • Savara Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Savara Inc.,
      • Sealife PHARMA GMBH
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sealife PHARMA GMBH,
      • Sentinella Pharmaceuticals, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sentinella Pharmaceuticals,
      • Sequoia Sciences Inc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sequoia Sciences Inc,
      • Soligenix, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Soligenix, Inc.,
      • Sorrento Therapeutics Inc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Sorrento Therapeutics Inc,
      • Taejoon Pharm Co., Ltd.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Taejoon Pharm Co., Ltd.,
      • TAXIS Pharmaceuticals, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TAXIS Pharmaceuticals, Inc.,
      • Telephus Medical LLC
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Telephus Medical LLC,
      • Tetraphase Pharmaceuticals Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Tetraphase Pharmaceuticals
      • TGV-Laboratories
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by TGV-Laboratories,
      • Theravance Biopharma Inc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Theravance Biopharma Inc,
      • Trellis Bioscience, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Trellis Bioscience, Inc.,
      • Valevia UK Limited
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Valevia UK Limited,
      • VLP Biotech, Inc.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by VLP Biotech, Inc.,
      • Wintermute Biomedical LLC
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wintermute Biomedical LLC,
      • Wockhardt Limited
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Wockhardt Limited,
      • XBiotech Inc
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by XBiotech Inc,
      • Yungjin Pharm. Co., Ltd.
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Yungjin Pharm. Co., Ltd.,
      • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Allergan Plc,
      • Galapagos NV
        • Table Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Galapagos NV,
      • Merck & Co Inc
        • Table Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Merck & Co Inc,
      • Syntiron LLC
        • Table Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Syntiron LLC,
      • Valevia UK Ltd
        • Table Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline by Valevia UK Ltd,
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Destiny Pharma Ltd,
      • Galapagos NV
        • Table Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Galapagos NV,
      • MGB Biopharma Ltd
        • Table Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by MGB Biopharma Ltd,
      • Syntiron LLC
        • Table Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Syntiron LLC,
      • Techulon Inc
        • Table Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Techulon Inc,
      • Valevia UK Ltd
        • Table Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline by Valevia UK Ltd,
  • Therapeutics Assessment
    • Tuberculosis
      • Assessment by Monotherapy Products
        • Table Figure 50: Assessment by Monotherapy Products, Tuberculosis
        • Table Assessment by Monotherapy Products, Tuberculosis
      • Assessment by Combination Products
        • Table Figure 51: Assessment by Combination Products, Tuberculosis
        • Table Assessment by Combination Products, Tuberculosis
      • Assessment by Target
        • Table Figure 52: Number of Products by Top 10 Targets, Tuberculosis
        • Table Figure 53: Number of Products by Stage and Top 10 Targets, Tuberculosis
        • Table Number of Products by Stage and Target, Tuberculosis
      • Assessment by Mechanism of Action
        • Table Figure 54: Number of Products by Top 10 Mechanism of Actions, Tuberculosis
        • Table Figure 55: Number of Products by Stage and Top 10 Mechanism of Actions, Tuberculosis
        • Table Number of Products by Stage and Mechanism of Action, Tuberculosis
      • Assessment by Route of Administration
        • Table Figure 56: Number of Products by Top 10 Routes of Administration, Tuberculosis
        • Table Figure 57: Number of Products by Stage and Top 10 Routes of Administration, Tuberculosis
        • Table Number of Products by Stage and Route of Administration, Tuberculosis
      • Assessment by Molecule Type
        • Table Figure 58: Number of Products by Top 10 Molecule Types, Tuberculosis
        • Table Figure 59: Number of Products by Stage and Top 10 Molecule Types, Tuberculosis
        • Table Number of Products by Stage and Molecule Type, Tuberculosis
    • Pneumonia
      • Community Acquired Pneumonia
        • Table Figure 60: Assessment by Monotherapy Products, Community Acquired Pneumonia
        • Table Assessment by Monotherapy Products, Community Acquired Pneumonia
      • Assessment by Target
        • Table Figure 61: Number of Products by Targets, Community Acquired Pneumonia
        • Table Figure 62: Number of Products by Stage and Targets, Community Acquired Pneumonia
        • Table Number of Products by Stage and Target, Community Acquired Pneumonia
      • Assessment by Mechanism of Action
        • Table Figure 63: Number of Products by Mechanism of Actions, Community Acquired Pneumonia
        • Table Figure 64: Number of Products by Stage and Mechanism of Actions, Community Acquired Pneumonia
        • Table Number of Products by Stage and Mechanism of Action, Community Acquired Pneumonia
      • Assessment by Route of Administration
        • Table Figure 65: Number of Products by Routes of Administration, Community Acquired Pneumonia
        • Table Figure 66: Number of Products by Stage and Routes of Administration, Community Acquired Pneumonia
        • Table Number of Products by Stage and Route of Administration, Community Acquired Pneumonia
      • Assessment by Molecule Type
        • Table Figure 67: Number of Products by Molecule Types, Community Acquired Pneumonia
        • Table Figure 68: Number of Products by Stage and Top 10 Molecule Types, Community Acquired Pneumonia
        • Table Number of Products by Stage and Molecule Type, Community Acquired Pneumonia
      • Hospital Acquired Pneumonia (HAP)
        • Table Figure 69: Assessment by Monotherapy Products, Hospital Acquired Pneumonia (HAP)
        • Table Assessment by Monotherapy Products, Hospital Acquired Pneumonia (HAP)
      • Assessment by Combination Products
        • Table Figure 70: Assessment by Combination Products, Hospital Acquired Pneumonia (HAP)
        • Table Assessment by Combination Products, Hospital Acquired Pneumonia (HAP)
      • Assessment by Target
        • Table Figure 71: Number of Products by Top 10 Targets, Hospital Acquired Pneumonia (HAP)
        • Table Figure 72: Number of Products by Stage and Top 10 Targets, Hospital Acquired Pneumonia (HAP)
        • Table Number of Products by Stage and Target, Hospital Acquired Pneumonia (HAP)
      • Assessment by Mechanism of Action
        • Table Figure 73: Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP)
        • Table Figure 74: Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP)
        • Table Number of Products by Stage and Mechanism of Action, Hospital Acquired Pneumonia (HAP)
      • Assessment by Route of Administration
        • Table Figure 75: Number of Products by Routes of Administration, Hospital Acquired Pneumonia (HAP)
        • Table Figure 76: Number of Products by Stage and Routes of Administration, Hospital Acquired Pneumonia (HAP)
        • Table Number of Products by Stage and Route of Administration, Hospital Acquired Pneumonia (HAP)
      • Assessment by Molecule Type
        • Table Figure 77: Number of Products by Molecule Types, Hospital Acquired Pneumonia (HAP)
        • Table Figure 78: Number of Products by Stage and Molecule Types, Hospital Acquired Pneumonia (HAP)
        • Table Number of Products by Stage and Molecule Type, Hospital Acquired Pneumonia (HAP)
      • Ventilator Associated Pneumonia (VAP)
        • Table Figure 79: Assessment by Monotherapy Products, Ventilator Associated Pneumonia (VAP)
        • Table Assessment by Monotherapy Products, Ventilator Associated Pneumonia (VAP)
      • Assessment by Combination Products
        • Table Figure 80: Assessment by Combination Products, Ventilator Associated Pneumonia (VAP)
        • Table Assessment by Combination Products, Ventilator Associated Pneumonia (VAP)
      • Assessment by Target
        • Table Figure 81: Number of Products by Top 10 Targets, Ventilator Associated Pneumonia (VAP)
        • Table Figure 82: Number of Products by Stage and Top 10 Targets, Ventilator Associated Pneumonia (VAP)
        • Table Number of Products by Stage and Target, Ventilator Associated Pneumonia (VAP)
      • Assessment by Mechanism of Action
        • Table Figure 83: Number of Products by Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP)
        • Table Figure 84: Number of Products by Stage and Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP)
        • Table Number of Products by Stage and Mechanism of Action, Ventilator Associated Pneumonia (VAP)
      • Assessment by Route of Administration
        • Table Figure 85: Number of Products by Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP)
        • Table Figure 86: Number of Products by Stage and Top 10 Routes of Administration, Ventilator Associated Pneumonia
        • Table Number of Products by Stage and Route of Administration, Ventilator Associated Pneumonia (VAP)
      • Assessment by Molecule Type
        • Table Figure 87: Number of Products by Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP)
        • Table Figure 88: Number of Products by Stage and Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP)
        • Table Number of Products by Stage and Molecule Type, Ventilator Associated Pneumonia (VAP)
      • Pseudomonas aeruginosa Infections
        • Table Figure 89: Assessment by Monotherapy Products, Pseudomonas aeruginosa Infections
        • Table Assessment by Monotherapy Products, Pseudomonas aeruginosa Infections
      • Assessment by Combination Products
        • Table Figure 90: Assessment by Combination Products, Pseudomonas aeruginosa Infections
        • Table Assessment by Combination Products, Pseudomonas aeruginosa Infections
      • Assessment by Target
        • Table Figure 91: Number of Products by Top 10 Targets, Pseudomonas aeruginosa Infections
        • Table Figure 92: Number of Products by Stage and Top 10 Targets, Pseudomonas aeruginosa Infections
        • Table Number of Products by Stage and Target, Pseudomonas aeruginosa Infections
      • Assessment by Mechanism of Action
        • Table Figure 93: Number of Products by Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections
        • Table Figure 94: Number of Products by Stage and Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections
        • Table Number of Products by Stage and Mechanism of Action, Pseudomonas aeruginosa Infections
      • Assessment by Route of Administration
        • Table Figure 95: Number of Products by Routes of Administration, Pseudomonas aeruginosa Infections
        • Table Figure 96: Number of Products by Stage and Routes of Administration, Pseudomonas aeruginosa Infections
        • Table Number of Products by Stage and Route of Administration, Pseudomonas aeruginosa Infections
      • Assessment by Molecule Type
        • Table Figure 97: Number of Products by Top 10 Molecule Types, Pseudomonas aeruginosa Infections
        • Table Figure 98: Number of Products by Stage and Top 10 Molecule Types, Pseudomonas aeruginosa Infections
        • Table Number of Products by Stage and Molecule Type, Pseudomonas aeruginosa Infections
      • Klebsiella pneumoniae Infections
        • Table Figure 99: Assessment by Monotherapy Products, Klebsiella pneumoniae Infections
        • Table Assessment by Monotherapy Products, Klebsiella pneumoniae Infections
      • Assessment by Target
        • Table Figure 100: Number of Products by Top 10 Targets, Klebsiella pneumoniae Infections
        • Table Figure 101: Number of Products by Stage and Top 10 Targets, Klebsiella pneumoniae Infections
        • Table Number of Products by Stage and Target, Klebsiella pneumoniae Infections
      • Assessment by Mechanism of Action
        • Table Figure 102: Number of Products by Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections
        • Table Figure 103: Number of Products by Stage and Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections
        • Table Number of Products by Stage and Mechanism of Action, Klebsiella pneumoniae Infections
      • Assessment by Route of Administration
        • Table Figure 104: Number of Products by Routes of Administration, Klebsiella pneumoniae Infections
        • Table Figure 105: Number of Products by Stage and Routes of Administration, Klebsiella pneumoniae Infections
        • Table Number of Products by Stage and Route of Administration, Klebsiella pneumoniae Infections
      • Assessment by Molecule Type
        • Table Figure 106: Number of Products by Molecule Types, Klebsiella pneumoniae Infections
        • Table Figure 107: Number of Products by Stage and Molecule Types, Klebsiella pneumoniae Infections
        • Table Number of Products by Stage and Molecule Type, Klebsiella pneumoniae Infections
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Figure 108: Assessment by Monotherapy Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Assessment by Monotherapy Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Assessment by Combination Products
        • Table Figure 109: Assessment by Combination Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Assessment by Combination Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Assessment by Target
        • Table Figure 110: Number of Products by Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Figure 111: Number of Products by Stage and Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Number of Products by Stage and Target, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Assessment by Mechanism of Action
        • Table Figure 112: Number of Products by Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Figure 113: Number of Products by Stage and Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Number of Products by Stage and Mechanism of Action, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Assessment by Route of Administration
        • Table Figure 114: Number of Products by Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Figure 115: Number of Products by Stage and Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Number of Products by Stage and Route of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Assessment by Molecule Type
        • Table Figure 116: Number of Products by Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Figure 117: Number of Products by Stage and Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Number of Products by Stage and Molecule Type, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Figure 118: Assessment by Monotherapy Products, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Assessment by Monotherapy Products, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
      • Assessment by Target
        • Table Figure 119: Number of Products by Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CAMRSA) Infections
        • Table Figure 120: Number of Products by Stage and Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Number of Products by Stage and Target, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
      • Assessment by Mechanism of Action
        • Table Figure 121: Number of Products by Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Figure 122: Number of Products by Stage and Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Number of Products by Stage and Mechanism of Action, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
      • Assessment by Route of Administration
        • Table Figure 123: Number of Products by Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Figure 124: Number of Products by Stage and Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Number of Products by Stage and Route of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
      • Assessment by Molecule Type
        • Table Figure 125: Number of Products by Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Figure 126: Number of Products by Stage and Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Number of Products by Stage and Molecule Type, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Figure 127: Assessment by Monotherapy Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Assessment by Monotherapy Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
      • Assessment by Target
        • Table Figure 128: Number of Products by Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HAMRSA) Infections
        • Table Figure 129: Number of Products by Stage and Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Number of Products by Stage and Target, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
      • Assessment by Mechanism of Action
        • Table Figure 130: Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Figure 131: Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Number of Products by Stage and Mechanism of Action, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
      • Assessment by Route of Administration
        • Table Figure 132: Number of Products by Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Figure 133: Number of Products by Stage and Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Number of Products by Stage and Route of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
      • Assessment by Molecule Type
        • Table Figure 134: Number of Products by Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Figure 135: Number of Products by Stage and Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Number of Products by Stage and Molecule Type, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Dormant Projects
    • Tuberculosis
      • Table Tuberculosis - Dormant Projects,
    • Pneumonia
      • Community Acquired Pneumonia
        • Table Community Acquired Pneumonia - Dormant Projects,
      • Hospital Acquired Pneumonia (HAP)
        • Table Hospital Acquired Pneumonia (HAP) - Dormant Projects,
      • Ventilator Associated Pneumonia (VAP)
        • Table Ventilator Associated Pneumonia (VAP) - Dormant Projects,
      • Pseudomonas aeruginosa Infections
        • Table Pseudomonas aeruginosa Infections - Dormant Projects,
      • Klebsiella pneumoniae Infections
        • Table Klebsiella pneumoniae Infections - Dormant Projects,
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects,
      • Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
        • Table Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Dormant Projects,
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects,
  • Discontinued Products
    • Tuberculosis
      • Table Tuberculosis - Discontinued Products,
    • Pneumonia
      • Community Acquired Pneumonia
        • Table Community Acquired Pneumonia - Discontinued Products,
      • Hospital Acquired Pneumonia (HAP)
        • Table Hospital Acquired Pneumonia (HAP) - Discontinued Products,
      • Ventilator Associated Pneumonia (VAP)
        • Table Ventilator Associated Pneumonia (VAP) - Discontinued Products,
      • Pseudomonas aeruginosa Infections
        • Table Pseudomonas aeruginosa Infections - Discontinued Products,
      • Klebsiella pneumoniae Infections
        • Table Klebsiella pneumoniae Infections - Discontinued Products,
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
        • Table Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products,
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
        • Table Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Discontinued Products,
  • Product Development Milestones
    • Tuberculosis
      • Featured News & Press Releases
      • Feb 24, 2016: Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership Global Drug Facility
      • Sep 17, 2015: IDRI And Wellcome Trust Team For Tuberculosis Vaccine Trial In South Africa
      • Aug 24, 2015: Janssen's SIRTURO to be commissioned by NHS England for the treatment of multi-drug resistant tuberculosis
      • Jul 16, 2015: Efficacy Results of Otsuka's Delamanid (Deltyba) for Extensively Drug-Resistant Tuberculosis Published in the New England Journal of Medicine
      • Jul 08, 2015: Start of phase 2 trial in newborn infants in South Africa with VPM1002, a new vaccine developed by an Indo-German co-operation for prevention of tuberculosis
      • May 19, 2015: Lakewood-Amedex Announces Its Novel Bisphospocin Class Of Antimicrobials Kills Multidrug Resistant-Tuberculosis (MDR-TB) Strains In Fifteen Minutes
      • Mar 24, 2015: World-first TB vaccination trials enter next stage
      • Mar 24, 2015: SAKK studies effect of new tuberculosis vaccine on bladder cancer
      • Mar 18, 2015: Global Phase 3 "STAND" Trial Launched to Test New Tuberculosis Drug Regimen PaMZ to Shorten, Improve Treatment
      • Mar 18, 2015: The Lancet: Results of Phase 2b Trial of Novel TB Regimen PaMZ Show Potential to Shorten, Improve TB Treatment
      • Jan 29, 2015: Phase 2a Published Results Show the Potential of a New TB Regimen with Novel Drugs Bedaquiline and Pretomanid (PA-824)
      • Dec 04, 2014: BioVersys and Universite de Lille achieve first milestone in tuberculosis collaboration with GlaxoSmithKline
      • Nov 06, 2014: Janssen Collaborates for Continued Evaluation of Multidrug-Resistant Tuberculosis Treatment Regimens with SIRTURO (bedaquiline)
      • Oct 22, 2014: TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients
    • Pneumonia
      • Community Acquired Pneumonia
      • Hospital Acquired Pneumonia (HAP)
      • Ventilator Associated Pneumonia (VAP)
      • Pseudomonas aeruginosa Infections
      • Klebsiella pneumoniae Infections
    • Methicillin-Resistant Staphylococcus aureus (MRSA)
      • Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
      • Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report